ArticleMolecular cancer therapeutics2025

Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47.

Matthew R Levengood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.